<DOC>
	<DOCNO>NCT01834898</DOCNO>
	<brief_summary>The hypothesis study control release oxycodone safe well tolerate control postoperative pain surgery head neck cancer . The primary objective study safety incidence severity adverse effect , secondary objective evaluate analgesic efficacy identify frequency use rescue medication prescribe physician 's opinion quality postoperative analgesia oxycodone control release oncologic surgery head neck .</brief_summary>
	<brief_title>Safety Tolerability Controlled-release Oxycodone Postoperative Pain Oncologic Head Neck Surgery</brief_title>
	<detailed_description>Phase IV clinical trial , observational , prospective , open approve Research Ethics Committee National Cancer Institute José Alencar Gomes da Silva - INCA , Brazil ( . 10/2010 ) . The Instrument Consent sign patient . Eighty-three patient include . Ages 18 70 year gender , 2 3 American Society Anesthesiologists physical status , present moderate severe pain source postoperative surgical oncology , head neck , medium large , elective , non-emergency , able swallow tablet whole ( chew , break crush ) immediate postoperative period recovery cognitive function . Will exclude pregnant breastfeeding , allergic oxycodone opioids , gastrectomized colostomized , asthmatic severe organ dysfunction , history suspect paralytic ileus , history psychiatric disorder , severe respiratory depression , patient receive opioid analgesic baseline , history abuse alcohol illicit drug , patient present plasma glutamic oxaloacetic transaminase 48 U / l ( men ) 40 U / I ( woman ) / glutamic pyruvic transaminase 53 U / l ( men ) 40 U / I ( woman ) patient present plasma creatinine 1.7 mg / dl / urea 65 mg / dl . All patient assess preoperatively seven one day surgery ( visit 1 ) sign consent form , proceed pre-anesthetic evaluation blood collect laboratory test : complete blood count , β-human chorionic gonadotropin ( woman ) , glutamic oxaloacetic transaminase , glutamic pyruvic transaminase , creatinine urea . In immediate postoperative period ( visit 2 ) , pain assessed verbal numeric scale ( VNS ) pain moderate severe ( ≥ 4 EVN ) patient lucid able swallow , start orally controlled-release oxycodone ( Oxycontin , Zodiac Pharmaceuticals , Brazil ) dose 20 mg ( tablet whole without crush division ) , administer investigator . Every 12 hour subsequent period 48 hour first dose oxycodone controlled-release , pain evaluate , occurrence intensity adverse event ( visit 3 , 4 , 5 6 respectively 12 , 24 , 36 48 hour first dose oxycodone ) . The dos controlled-release oxycodone standardize follow : first day postoperatively , 40 mg / day divide 20 mg 12 12 hour second postoperative day , 20 mg / day divide 10 mg 12 12 hour . The rescue medication use non opioids analgesic paracetamol , dipyrone , diclofenac tenoxicam , first administration controlled-release oxycodone postoperatively . During visit describe annotated rescue analgesia frequency , ever use dose oxycodone . Between post-operative 7 13 day hold visit 7 , evaluate pain intensity ( EVN ) , occurrence severity adverse effect , investigator 's opinion treatment . Finally , patient 's blood collect perform test list visit 1 , except β-human chorionic gonadotropin ( woman ) , study terminate . Sample Size Statistical Analysis When consider occurrence nausea 25 % safety parameter , assessed literature data , number patient require 72 . Taking consideration dropout 20 % require 86 patient total ( accuracy 10 % , around percentage confidence interval ( CI ) 95 % ) . The study normal age variable conduct test Kolmogorov - Smirnov . The Friedman test use compare median pain intensity visit 2 visit 7 . The Dunn test use post-hoc comparison ( two ) median pain intensity ( p &lt; 0.001 - significant ) . The McNemar test pairwise comparison proportion employ comparison adverse event ( visit 4 , 5 , 6 7 respect visit 3 ) ( p &lt; 0.05 = significant ) . The remain data present frequency .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>patient postoperative head neck oncologic surgery 2 3 American Society Anesthesiologists physical status moderate severe postoperative pain elective surgery able swallow tablet whole ( chew , break crush ) immediate postoperative period recovery cognitive function . pregnant breastfeed allergic oxycodone opioids gastrectomized colostomized asthmatic severe organ dysfunction history suspect paralytic ileus history psychiatric disorder severe respiratory depression patient receive opioid analgesic baseline history abuse alcohol illicit drug plasma glutamic oxaloacetic transaminase 48 U / l ( men ) 40 U / I ( woman ) / glutamic pyruvic transaminase 53 U / l ( men ) 40 U / I ( woman ) plasma creatinine 1.7 mg / dl / urea 65 mg / dl emergency surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>postoperative</keyword>
	<keyword>analgesia</keyword>
	<keyword>adverse effect</keyword>
	<keyword>opioid</keyword>
	<keyword>oxycodone</keyword>
</DOC>